<DOC>
	<DOCNO>NCT01433458</DOCNO>
	<brief_summary>This study ass pharmacokinetics RLX030 administration subject mild severe hepatic impairment match healthy control subject . 20 24 patient 20 24 healthy subject enrol .</brief_summary>
	<brief_title>Pharmacokinetics RLX030 Subjects With Mild , Moderate Severe Hepatic Impairment Compared Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Inclusion criterion : All subject : â€¢ Female subject must nonchild bear potential OR use effective method contraception sexually active male must use condom intercourse take drug 5 halflives stop treatment Subjects hepatic impairment : Subjects must either mild , moderate severe hepatic impairment Exclusion criterion : All subject Hepatic impairment due nonliver disease Use investigational drug time enrollment History malignancy organ system Donation loss 400 mL blood plasma within 8 week prior initial dose Hemoglobin level 10.0 g/dL screen baseline Subjects hepatic impairment : Presence noncontrolled clinically significant disease could affect study outcome would place patient undue risk Treatment cytostatic drug , vasodilator , autonomic alpha blocker B2 agonist Any surgical medical condition hepatic impairment might significantly alter distribution excretion drug Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Hepatic impairment</keyword>
	<keyword>healthy volunteer</keyword>
	<keyword>RLX030</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>